URMC / Research / Clinical Trials / Study Details Breast Cancer: MK-3475 as Adjuvant therapy for Triple Receptor-Negative Breast Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy - S1418 Research Question:Does the drug MK-3475 help the survival of patients with breast cancer?Basic Study Information Purpose:The purpose of this study is to compare treated subjects' invasive disease-free survival of patients with triple-negative breast cancer after neoadjuvant chemotherapy. Location: University of Rochester Medical CenterStudy Reference #: CBRS18089Lead Researcher (Principal Investigator) Lead Researcher: Alissa Huston Study Contact InformationStudy Coordinator: Laura MitchellPhone: (585) 275-7763Email: Laura_Mitchell@URMC.Rochester.edu Additional Study Details Contact This Study First Name * This field is required Middle Name Last Name * This field is required Phone Number Email I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *You must agree to be contacted to continue. Please call me during the day. Please call me during the evening. Message Thank you for contacting us. People like you are helping URMC make our community and world a healthier place. We sincerely appreciate your effort. A member of our research team will be in touch with you. URMC / Wilmot Cancer Institute /Research / Clinical Trials / Study Details Trial Not Found The study you are looking for is not active at this time. Return to Search